Related Experiment Video
Updated: Feb 24, 2026
The Tail Suspension Test
Published on: January 28, 2012
Lithium nephrotoxicity: a systematic review and meta-analysis of lithium versus non-lithium control studies in
Marie Michele Macaron1,2, Mireilla Abou Rjeily3, Raphael Macaron4
1School of Medicine, St. George's University of London, London, UK.
Background:
Lithium, the gold standard treatment of bipolar disorder (BD), is thought to cause nephropathy in long-term users. However, the role of confounding variables linked to BD in exerting this adverse effect remains unclear.
Objectives:
This paper evaluates kidney function in patients with affective disorders who are taking lithium compared to patients not on lithium treatment.
Design:
This article is a systematic review and meta-analysis.
Data Sources And Methods:
A comprehensive search of publications up to October 2023 within Cochrane, Embase, PubMed, Scopus, Web of Science, and CINAHL databases was performed. Three assessors screened and extracted data from eligible observational studies. Risk of bias assessment was done with the ROBINS-E tool. Eligible studies were comparative studies of adult patients with diagnoses of affective disorders, including BD on lithium, with control groups not on lithium, reporting kidney function outcomes.
Results:
Mean estimated Glomerular filtration rate (eGFR) showed less favorable outcomes in the lithium group compared to the non-lithium group (n = 1622, MD = -11.14 ml/min/1.73 m2, 95% CI: -16.61, -5.68, I 2 = 86%). The mean annual eGFR decline comparison favored the non-lithium group (n = 13,280, MD = 0.13 ml/min/1.73 m2, 95% CI: 0.06, 0.20,I 2 = 0%). Serum creatinine concentration (mg/dl) was found to be higher in the lithium compared to non-lithium groups (n = = 1704, MD = 0.05, 95% CI: 0.03, 0.07,I 2 = 3%). New or progressing chronic kidney disease events were not found to be statistically different between the lithium and control groups (n = = 17,740, OR = 2.16, 95% CI: 0.59, 7.94,I 2 = 99%). The high heterogeneity in this meta-analysis limits the reliability and interpretability of our results.
Conclusion:
Kidney function, as measured by eGFR, was decreased in the lithium-taking groups versus the non-lithium groups. Continuous monitoring and discussion of risks and benefits with patients, especially those with a baseline of reduced kidney function, is imperative.
Trial Registration:
This review was registered prospectively with PROSPERO (CRD42024517414).
Related Concept Videos
01:24Mania and Antimanic Drugs: Overview
01:28Drug Therapy
Antianxiety Medications
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
01:30Electroconvulsive Therapy
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:30Bipolar Disorder